Early data on long-term efficacy and safety of inotersen in patients with hereditary transthyretin amyloidosis: a 2-year update from the open-label extension of the NEURO-TTR trial - Brannagan, T H; Wang, A K; Coelho, T; NEURO-TTR open-label extension investigators (Eur J Neurol, 2020)